CKPT Latest Press Releases, Checkpoint Therapeutics Corporate News

Releases

4.260

+0.95%

0.040

All
Financials
Insiders

4 | Checkpoint Therapeutics, Inc.(0001651407)
10/01/2024 19:50
SC 13D/A | Checkpoint Therapeutics, Inc.(0001651407)
10/01/2024 19:49
UPLOAD | Checkpoint Therapeutics, Inc.(0001651407)
09/30/2024 02:04
CORRESP | Checkpoint Therapeutics, Inc.(0001651407)
09/30/2024 02:02
EFFECT | Checkpoint Therapeutics, Inc.(0001651407)
09/03/2024 02:05
S-3 | Checkpoint Therapeutics, Inc.(0001651407)
08/19/2024 13:15
10-Q | Checkpoint Therapeutics, Inc.(0001651407)
08/12/2024 12:41
8-K | Checkpoint Therapeutics, Inc.(0001651407)
08/12/2024 04:46
8-K | Checkpoint Therapeutics, Inc.(0001651407)
07/25/2024 12:06
8-K | Checkpoint Therapeutics, Inc.(0001651407)
07/03/2024 04:45
424B5 | Checkpoint Therapeutics, Inc.(0001651407)
07/03/2024 04:40
4 | Checkpoint Therapeutics, Inc.(0001651407)
06/28/2024 16:02
4 | Checkpoint Therapeutics, Inc.(0001651407)
06/28/2024 16:01
8-K | Checkpoint Therapeutics, Inc.(0001651407)
06/24/2024 03:47
4 | Checkpoint Therapeutics, Inc.(0001651407)
05/24/2024 17:02
4 | Checkpoint Therapeutics, Inc.(0001651407)
05/24/2024 17:01
S-8 | Checkpoint Therapeutics, Inc.(0001651407)
05/24/2024 12:07
3 | Checkpoint Therapeutics, Inc.(0001651407)
05/24/2024 12:07
SC 13D/A | Checkpoint Therapeutics, Inc.(0001651407)
05/17/2024 13:14
4 | Checkpoint Therapeutics, Inc.(0001651407)
05/16/2024 15:36
4 | Checkpoint Therapeutics, Inc.(0001651407)
05/16/2024 15:35
4 | Checkpoint Therapeutics, Inc.(0001651407)
05/16/2024 15:34
4 | Checkpoint Therapeutics, Inc.(0001651407)
05/16/2024 15:33
4 | Checkpoint Therapeutics, Inc.(0001651407)
05/16/2024 15:32
4 | Checkpoint Therapeutics, Inc.(0001651407)
05/16/2024 15:31
8-K | Checkpoint Therapeutics, Inc.(0001651407)
05/14/2024 03:33
10-Q | Checkpoint Therapeutics, Inc.(0001651407)
05/10/2024 12:18
8-K | Checkpoint Therapeutics, Inc.(0001651407)
05/10/2024 04:46
UPLOAD | Checkpoint Therapeutics, Inc.(0001651407)
05/03/2024 11:36
CORRESP | Checkpoint Therapeutics, Inc.(0001651407)
05/03/2024 11:36
EFFECT | Checkpoint Therapeutics, Inc.(0001651407)
04/08/2024 02:04
DEF 14A | Checkpoint Therapeutics, Inc.(0001651407)
04/02/2024 02:08
DEFA14A | Checkpoint Therapeutics, Inc.(0001651407)
04/02/2024 02:08
S-3 | Checkpoint Therapeutics, Inc.(0001651407)
03/29/2024 13:04
SC 13D/A | Checkpoint Therapeutics, Inc.(0001651407)
03/22/2024 14:25
4 | Checkpoint Therapeutics, Inc.(0001651407)
03/22/2024 14:25
PRE 14A | Checkpoint Therapeutics, Inc.(0001651407)
03/22/2024 13:20
10-K | Checkpoint Therapeutics, Inc.(0001651407)
03/22/2024 13:14
8-K | Checkpoint Therapeutics, Inc.(0001651407)
03/22/2024 04:53
3 | Checkpoint Therapeutics, Inc.(0001651407)
03/19/2024 16:01
8-K | Checkpoint Therapeutics, Inc.(0001651407)
03/18/2024 12:06
4 | Checkpoint Therapeutics, Inc.(0001651407)
03/01/2024 15:32
4 | Checkpoint Therapeutics, Inc.(0001651407)
03/01/2024 15:31
SC 13G/A | Checkpoint Therapeutics, Inc.(0001651407)
02/14/2024 09:25
4 | Checkpoint Therapeutics, Inc.(0001651407)
02/02/2024 15:16
4 | Checkpoint Therapeutics, Inc.(0001651407)
02/02/2024 15:11
5 | Checkpoint Therapeutics, Inc.(0001651407)
02/02/2024 15:06
8-K | Checkpoint Therapeutics, Inc.(0001651407)
02/02/2024 12:17
424B5 | Checkpoint Therapeutics, Inc.(0001651407)
01/30/2024 12:11
8-K | Checkpoint Therapeutics, Inc.(0001651407)
01/30/2024 12:02

Webull provides the latest Checkpoint Therapeutics (CKPT) stock and general news. This information may help you make smarter investment decisions.

About CKPT

Checkpoint Therapeutics, Inc. is a commercial-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Its product candidates include UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cSCC or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Additionally, the Company is engaged in evaluating its lead investigational small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.